‘We’re On The Edge Of Knowledge,’ Says Dewpoint CEO
Executive Summary
Biomolecular condensates were first observed over 100 years ago, but their function – and the role they might play in a broad range of diseases – is only now being rigorously explored by drug developers. New technological development is helping scientists recreate condensates in laboratory conditions, providing insight into fundamental cellular processes. Amir Nashat, CEO of Dewpoint Therapeutics, told In Vivo that the company, following a recent $77m series B round, now has the resources to get to proof of concept for drugs targeting biomolecular condensates.
You may also be interested in...
Faze Is Newest Swimmer In Pool of Biotechs Targeting Biomolecular Condensates
Buoyed by an $81m Series A financing round, Faze Medicines joins Dewpoint Therapeutics and Nereid Therapeutics in the race to develop small-molecule drugs targeting biomolecular condensates, an emerging field of cell biology.
Khushboo Sharma: Improving Regulatory Science, From Industry To FDA And Back
From pre-med to pharma lab rat to deputy director of operations at the FDA, Khushboo Sharma, a 2021 In Vivo Rising Leader and current VP of science and regulatory affairs at BIO, has spent her career pursuing a goal she says the FDA and biopharma industry have in common: ensuring that innovative drugs get to patients.
Data-Sharing Key To US Supply Chain Resilience And Keeping Drug Costs Under Control
Aside from a few high-profile exceptions, the biopharma industry supply chain has remained secure and resilient during the COVID-19 pandemic, outperforming retail and consumer goods. Chip Davis, Jr., head of the Healthcare Distribution Alliance, spoke with In Vivo about the need for a long-term industrial policy for drug manufacturing, real-time data-sharing and transparency in the supply chain, and minimizing disruptions.